CLINICAL USE

Gastric acid suppression

DOSE IN NORMAL RENAL FUNCTION

10–120 mg daily, doses >100 mg in 2 divided doses

PHARMACOKINETICS

  • Molecular weight                           :381.4
  • %Protein binding                           :97
  • %Excreted unchanged in urine     : 0 (90 as metabolites)
  • Volume of distribution (L/kg)       :0.34
  • half-life – normal/ESRD (hrs)      :0.7–1.5/Unchanged

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

  • 20 to 50     : Dose as in normal renal function
  • 10 to 20     : Dose as in normal renal function
  • <10           : Dose as in normal renal function

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD                :Unlikely to be dialysed. Dose as in normal renal function
  • HD                     :Not dialysed. Dose as in normal renal function
  • HDF/high flux   :Unlikely to be dialysed. Dose as in normal renal function
  • CAV/VVHD      :Unlikely to be dialysed. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugs

  • Antifungals: absorption of itraconazole and ketoconazole reduced

    ADMINISTRATION

    Reconstition

    –

    Route

    Oral

    Rate of Administration

    –

    Comments

    –

    OTHER INFORMATION

    Interstitial nephritis has been reported with rabeprazole sodium.

    • Tags:

    Related News

    ffddfd

    Hyperlipidemia